Embelin has been reported to enhance TRAIL-mediated apoptosis not only by upregulating the death receptors DR4 and DR5 in breast cancer cells, but also by downregulating cFLIPS in malignant glioma cells. This evidence concerns the gene TNFRSF10B and breast carcinoma.